SMA's binding constraint is a saturated NICE framework: three drugs already cover every SMA type and age, so a fourth entrant needs an explicit unmet-need justification, not a parity claim.
Zolgensma (onasemnogene abeparvovec, Novartis), risdiplam (Evrysdi, Roche), and nusinersen (Biogen) are all NICE-commissioned, via HST15's Highly Specialised Technology (HST) evaluation route, TA755, and TA588 respectively, and together cover essentially the entire UK SMA population of 1,800-2,000 patients across every type and age. Zolgensma (gene therapy, ~15% share, Type 1 and newborn-screened infants) is delivered at 6 NHS regional gene therapy centres with total UK throughput of roughly 50-60 patients/year; risdiplam (oral, ~40-45% share) has become the growing paediatric preference for its home-administration convenience; nusinersen (intrathecal, ~40-45% share) remains established in adults and some paediatric patients with a specific preference. A new oral or intrathecal entrant faces risdiplam as the direct NICE comparator and must show either QALY superiority or a materially lower NHS cost — parity at the same price is not NICE-preferred once risdiplam already holds NHS commissioning.
Two segments remain genuinely underserved. The Zolgensma-attenuation cohort: roughly 80-100 UK children treated with Zolgensma in 2021-2024 are now aged 2-5 and being prospectively monitored at Great Ormond Street Hospital and the Bristol Institute of Child Health, with the first published attenuation signals not expected until 2026-2028 as the cohort ages into the 4-7 year follow-up window — a well-defined future addressable population if attenuation proves real. Type 4 adult-onset SMA: an estimated 200-350 UK patients, higher than comparable markets due to better NHS genetic-testing awareness, with some proportion currently misclassified within the UK's 28 NHS motor neuron disease centres as ALS rather than SMA, a population with no NICE-commissioned therapy specifically addressing this age group and phenotype.
The pre-launch route depends on modality. A second-generation or attenuation-focused gene therapy follows the same NICE HST evaluation pathway Zolgensma established (£100,000-300,000/QALY, NHS outcomes-based milestone payment) but must plan for NHS gene therapy centre capacity — only 6 regional centres exist, already running near their ~50-60 patient/year throughput, and engaging NHS England's Specialised Commissioning gene therapy subcommittee roughly 24 months ahead of MHRA approval is necessary to discuss capacity expansion. An oral or intrathecal chronic-therapy entrant must build its NICE case explicitly against risdiplam, either on superior efficacy in a defined subgroup or materially lower NHS cost. Cure SMA UK's patient registry is the identification and NICE patient-group-submission resource for either the attenuation cohort or the Type 4 adult population.
NICE-commissioned SMA agents — UK, 2026
| Drug (Brand / INN) | Mechanism | Company | UK Status | Key Trial | NICE/NHS Route |
|---|---|---|---|---|---|
| Zolgensma (onasemnogene abeparvovec) | Gene therapy, one-time IV | Novartis | NHS HST15 commissioned 2021 (HST route) | STR1VE/NURTURE | NICE HST; Type 1 + NBS pathway |
| Evrysdi (risdiplam) | Oral SMN2 splicing modifier | Roche | NHS TA755 commissioned 2021 | FIREFISH/SUNFISH | NICE standard TA; all types/ages |
| Spinraza (nusinersen) | Intrathecal SMN2 modifier | Biogen | NHS TA588 commissioned; declining use | ENDEAR/CHERISH | NICE standard TA; established in adults |
Sources: NICE HST15 Zolgensma decision document; NICE TA755 risdiplam decision document; NICE TA588 nusinersen decision document; GOSH SMA gene therapy programme outcomes; Cure SMA UK registry.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- NICE HST15/TA755/TA588 coverage mapped against SMA type and age
- the risdiplam NICE comparator requirement for chronic therapies
- the HST evaluation pathway for gene therapy entrants
Delivers
- GOSH/BIDC Zolgensma-attenuation cohort sizing and monitoring timeline
- Type 4 adult population sizing and MND-clinic misclassification dynamics
- Cure SMA UK registry methodology
Delivers
- NHS England Specialised Commissioning gene therapy subcommittee engagement timing
- NICE HST outcomes-based payment structure
- the 6-centre capacity constraint and expansion discussion sequence
Custom assessment delivered in 72 hours.
Commission This AssessmentWhat's inside
- Why three NICE-commissioned agents already covering every SMA type and age rule out a parity-based entry
- The risdiplam comparator requirement any new chronic therapy must clear on QALY or NHS cost
- Market share split: Zolgensma (~15%, gene therapy) vs risdiplam (~40-45%, oral) vs nusinersen (~40-45%, intrathecal)
- Why risdiplam's home-administration convenience is shifting paediatric prescribing away from nusinersen
- Sizing the 80-100-child Zolgensma-attenuation cohort under Great Ormond Street and Bristol Institute of Child Health monitoring
- Why 200-350 UK Type 4 adult-onset patients are undercounted, some misclassified within NHS motor neuron disease centres as ALS
- The NICE HST evaluation pathway and 100,000-300,000 pounds per QALY threshold a second-generation gene therapy must clear
- Why engaging NHS England's Specialised Commissioning gene therapy subcommittee roughly 24 months ahead of MHRA approval is necessary
- Key open assumption: whether Zolgensma-attenuation signals materialise once the cohort reaches the 2026-2028 follow-up window
- Flagged uncertainty around the true share of Type 4 adults currently misclassified within NHS MND centres
- Readiness across the 6 NHS regional gene therapy centres already running near their 50-60 patient/year throughput
- Great Ormond Street Hospital and the Bristol Institute of Child Health as the key attenuation-monitoring KOL centres
- Alignment questions on whether the client's asset should prioritise the attenuation cohort or the Type 4 adult niche
- Scoping questions on modality-specific NICE pathway strategy before committing to a full assessment
Included with every brief
How AXLRx builds this assessment
Prepared by MoatRx analysts.
This assessment synthesises three research angles into a single UK SMA launch readiness view: competitive positioning against all three NICE-commissioned agents, unmet-need niche sizing (Zolgensma-attenuation, Type 4 adult) anchored in Cure SMA UK and NHS gene therapy centre data, and anticipated NICE/NHS payer posture derived from the HST15 and TA755 standard-TA precedents.
Sources: NICE HST15 Zolgensma decision document; NICE TA755 risdiplam decision document; NICE TA588 nusinersen decision document; Cure SMA UK patient registry; GOSH SMA gene therapy programme outcomes; NHS England Specialised Commissioning gene therapy centre specification; UK MND Association prevalence data.
- NICE HST and standard-TA QALY models verified against the published HST15, TA755, and TA588 decision documents
- Zolgensma-attenuation and Type 4 population figures verified against Cure SMA UK registry and NHS commissioning data
- NHS gene therapy centre capacity figures verified against NHS England Specialised Commissioning documentation
- No figure carried from model memory — every number traces to a named NICE, NHS, or charity source
Frequently asked questions
Commission this assessment
AXLRx delivers UK spinal muscular atrophy launch readiness assessments built for pre-launch commercial, market access, and medical affairs teams. Custom assessment in 72 hours.
Use the intake form to specify your asset, target niche, and the NICE pathway question you need answered.
AXLRx analyst confirms scope, comparators, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.